G1 Therapeutics Inc.

11/29/2021 | Press release | Distributed by Public on 11/29/2021 06:04

G1 Therapeutics Announces Initiation of New Phase 2 Trial of Trilaciclib in Combination with the Antibody-Drug Conjugate (ADC), Trodelvy® (Sacituzumab Govitecan-Hziy)